Christel Protiere

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5078065/publications.pdf

Version: 2024-02-01

566801 40 837 15 citations h-index papers

g-index 51 51 51 1070 docs citations times ranked citing authors all docs

500791

28

#	Article	IF	Citations
1	Determinants of Patients? Choice of Reconstruction with Mastectomy for Primary Breast Cancer. Annals of Surgical Oncology, 2004, 11, 762-771.	0.7	105
2	Eliciting several willingness to pay in a single contingent valuation survey: application to health care. Health Economics (United Kingdom), 2003, 12, 51-64.	0.8	70
3	Comparing WTP Values of Different Types of QALY Gain Elicited from the General Public. Health Economics (United Kingdom), 2015, 24, 280-293.	0.8	64
4	The labour market, psychosocial outcomes and health conditions in cancer survivors: protocol for a nationwide longitudinal survey 2 and 5 years after cancer diagnosis (the VICAN survey). BMJ Open, 2015, 5, e005971-e005971.	0.8	61
5	Efficacy and tolerance of a scalp-cooling system for prevention of hair loss and the experience of breast cancer patients treated by adjuvant chemotherapy. Supportive Care in Cancer, 2002, 10, 529-537.	1.0	53
6	Prescribers' attitudes toward elderly breast cancer patients. Discrimination or empathy?. Critical Reviews in Oncology/Hematology, 2010, 75, 138-150.	2.0	50
7	Patient participation in medical decision-making: A French study in adjuvant radio-chemotherapy for early breast cancer. Annals of Oncology, 2000, 11 , 39 - 46 .	0.6	46
8	The impact of information on non-health attributes on willingness to pay for multiple health care programmes. Social Science and Medicine, 2004, 58, 1257-1269.	1.8	41
9	Heterogeneity of Cancer Patient Information-Seeking Behaviors. Medical Decision Making, 2012, 32, 362-375.	1.2	38
10	BRCA1/2 carriers: their childbearing plans and theoretical intentions about having preimplantation genetic diagnosis and prenatal diagnosis. Genetics in Medicine, 2012, 14, 527-534.	1.1	34
11	Full access to medical records does not modify anxiety in cancer patients. Cancer, 2011, 117, 4796-4804.	2.0	28
12	Patterns of patient and healthcare provider viewpoints regarding participation in HIV cure-related clinical trials. Findings from a multicentre French survey using Q methodology (ANRS-APSEC). PLoS ONE, 2017, 12, e0187489.	1.1	24
13	From representing views to representativeness of views: Illustrating a new (Q2S) approach in the context of health care priority setting in nine European countries. Social Science and Medicine, 2016, 166, 205-213.	1.8	19
14	Acceptability of HIV cure-related trials: the challenges for physicians and people living with HIV (ANRS-APSEC). AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 914-920.	0.6	19
15	Cost-effectiveness of adjuvant docetaxel for node-positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology, 2010, 21, 1448-1454.	0.6	15
16	Differences in HIV cure clinical trial preferences of French people living with HIV and physicians in the ANRSâ€APSEC study: a discrete choice experiment. Journal of the International AIDS Society, 2020, 23, e25443.	1.2	14
17	What is the effect of self-identified HIV activism in willingness to participate in HIV cure-related clinical trials? Results from the ANRS-APSEC study. Journal of Virus Eradication, 2019, 5, 152-162.	0.3	13
18	Quality of life of breast cancer patients receiving high-dose-intensity chemotherapy: impact of length of cycles. Supportive Care in Cancer, 2002, 10, 222-230.	1.0	12

#	Article	IF	Citations
19	Impact of HIV risk perception on both pre-exposure prophylaxis and condom use. Journal of Health Psychology, 2021, 26, 1575-1586.	1.3	11
20	Transitions in the labor market after cancer: a comparison of self-employed workers and salaried staff. Supportive Care in Cancer, 2016, 24, 4879-4886.	1.0	10
21	What are the situational and behavioral factors associated with condomless anal sex without pre-exposure prophylaxis in MSM?. Aids, 2020, 34, 1367-1375.	1.0	9
22	Lung cancer in elderly patients: A retrospective analysis of practice in a single institution. Critical Reviews in Oncology/Hematology, 2007, 64, 43-48.	2.0	7
23	Importance of the patientâ€physician interaction in assessing acceptability of HIV cure trials. HIV Medicine, 2018, 19, e56-e57.	1.0	7
24	Changes in Sexual Behaviors in Men Who Have Sex with Men: A Comparison Between the Double-Blind and Open-Label Extension Phases of the ANRS-IPERGAY Trial. AIDS and Behavior, 2020, 24, 3093-3106.	1.4	7
25	Will CURE trials introduce an uncomfortable revolution in the field of HIV research?. HIV Clinical Trials, 2017, 18, 174-175.	2.0	6
26	What is the effect of self-identified HIV activism in willingness to participate in HIV cure-related clinical trials? Results from the ANRS-APSEC study. Journal of Virus Eradication, 2019, 5, 152-162.	0.3	6
27	Marketing Authorization Procedures for Advanced Cancer Drugs: Exploring the Views of Patients, Oncologists, Healthcare Decision Makers, and Citizens in France. Medical Decision Making, 2017, 37, 555-566.	1.2	5
28	The ANRS-Ipergay trial, an opportunity to use qualitative research to understand the perception of the "participant―physician relationship. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 41-47.	0.6	5
29	Les consentements à payer pour des programmes de prévention sanitaire incluent-ils de l'altruisme�. Revue Economique, 2004, Vol. 55, 923-945.	0.1	5
30	Modulations of dose intensity of doxorubicin and cyclophosphamide in association with G-CSF and peripheral blood stem cells in adjuvant chemotherapy for breast cancer: comparative evaluation of completion and safety of three intensive regimens. Bone Marrow Transplantation, 2002, 29, 881-886.	1.3	4
31	Who are the persons living with HIV who might refuse to participate in HIV cure-related clinical trials with treatment interruption?. Aids, 2020, 34, 1095-1099.	1.0	4
32	Characterization of Physicians That Might Be Reluctant to Propose HIV Cure-Related Clinical Trials with Treatment Interruption to Their Patients? The ANRS-APSEC Study. Vaccines, 2020, 8, 334.	2.1	4
33	How Can Contingent Valuation Inform theÂBioethics Debate? Evidence from aÂSurvey on Hereditary Cancers in France. Revue Economique, 2017, Vol. 68, 379-404.	0.1	2
34	Patients' self-assessment of tolerance and quality of life during docetaxel-based chemotherapy: Results from a phase III trial in hormone-naive metastatic prostate cancer patients (GETUG-AFU) Tj ETQq0 0 0 rg	BT (O verlo	ck 1 0 Tf 50 13
35	Take the Money and Run? Hypothetical Fee Variations and French GPs' Labour Supply. Revue Economique, 2017, Vol. 68, 357-377.	0.1	2
36	Les consentements a payer pour des programmes de prevention sanitaire incluent-ils de l'altruisme?: Enseignements d'une enquete sur la fievre Q. Revue Economique, 2004, 55, 923.	0.1	1

#	Article	IF	CITATIONS
37	$51\hat{a} \in fHIV$ patients and caregivers viewpoints towards participation to future HIV cure-related clinical trials $\hat{a} \in fHIV$ results from the second part of the French ANRS-APSEC survey. Journal of Virus Eradication, 2016, 2, 27.	0.3	1
38	Willingness to be informed during treatment among cancer patients?. Journal of Clinical Oncology, 2006, 24, 18522-18522.	0.8	0
39	Systematic versus on-request patients' access to medical files: Randomized trial—Influence on anxiety, quality of life and treatment satisfaction in cancer patients. Journal of Clinical Oncology, 2008, 26, 6524-6524.	0.8	O
40	Toxicity symptom reporting by patients and clinicians during phase III trial comparing androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in hormone-naÃ-ve metastatic prostate cancer (GETUG-AFU 15/0403) Journal of Clinical Oncology, 2010, 28, 6155-6155.	0.8	0